How A Global Biosimilars Company Cut Manual Data Errors By 50% Across 250+ Lab Workflows

Transitioning from manual laboratory processes to a digital-first strategy is a critical move for biopharmaceutical companies aiming to accelerate the delivery of high-quality biosimilars. For many organizations, the reliance on printing, archiving, and re-keying experimental data creates a significant operational burden, leading to frequent transcription errors and wasted time. By implementing a centralized informatics platform, researchers can eliminate these non-value-add tasks and focus more effectively on scientific innovation.

This case study examines how a global biopharmaceutical leader connected over 350 instruments and systems to orchestrate seamless, GxP-compliant workflows. The results highlight a 50% reduction in manual data entry errors and the successful adoption by over 400 users across multiple development sites. Discover how standardizing digital execution can yield defensible, real-time insights and significantly improve long-term sustainability by reviewing the full case study.